ERGO (Entia Biosciences) Total Liabilities: $2.41 Mil (As of Dec. 2016)


What is Entia Biosciences Total Liabilities?

Entia Biosciences ERGO Total Liabilities is $2.41 Mil as of Dec. 2016.

Entia Biosciences's Total Liabilities for the quarter that ended in Dec. 2016 was $2.41 Mil.

Entia Biosciences's quarterly Total Liabilities increased from Jun. 2016 ($1.79 Mil) to Sep. 2016 ($2.01 Mil) and increased from Sep. 2016 ($2.01 Mil) to Dec. 2016 ($2.41 Mil).

Entia Biosciences's annual Total Liabilities increased from Dec. 2014 ($0.99 Mil) to Dec. 2015 ($1.24 Mil) and increased from Dec. 2015 ($1.24 Mil) to Dec. 2016 ($2.41 Mil).

Entia Biosciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Entia Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entia Biosciences Total Liabilities Chart

Entia Biosciences Annual Data
Trend Jul07 Jul08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.11 1.58 0.99 1.24 2.41

Entia Biosciences Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.24 1.43 1.79 2.01 2.41

Entia Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Entia Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2016 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.106+(0.3+2.7755575615629E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.41

Total Liabilities=Total Assets (A: Dec. 2016 )-Total Equity (A: Dec. 2016 )
=0.439--1.967
=2.41

Entia Biosciences's Total Liabilities for the quarter that ended in Dec. 2016 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.106+(0.3+2.7755575615629E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.41

Total Liabilities=Total Assets (Q: Dec. 2016 )-Total Equity (Q: Dec. 2016 )
=0.439--1.967
=2.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $2.41 Mil mean?
Entia Biosciences (ERGO) has a Total Liabilities of $2.41 Mil as of Dec. 2016. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Entia Biosciences and its competitors.
Is Entia Biosciences' Total Liabilities too high?
Entia Biosciences' current Total Liabilities is $2.41 Mil.
How does Entia Biosciences' Total Liabilities compare to OBMP and NSPX?
Entia Biosciences' Total Liabilities of $2.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Entia Biosciences and its competitors. Entia Biosciences's current Total Liabilities is $2.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entia Biosciences stock overvalued right now?
Entia Biosciences (ERGO) has a current Total Liabilities of $2.41 Mil. The current Total Liabilities is $2.41 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Entia Biosciences (ERGO), the current Total Liabilities is $2.41 Mil as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entia Biosciences Business Description

Address 13565 South West Tualatin-Sherwood Road, Suite 800, Sherwood, OR, USA, 97140
Entia Biosciences Inc operates as a biotechnology company, is engaged in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products, principally in the United States of America. It market nutraceutical products under the name GROH and SANO directly to the consumers online. It currently offers natural organic nutraceutical mushroom dietary supplement products, ImmuSANO, GlucoSANO, and GROH, which has been designed to nutritionally support hair follicles and nail beds. It derives its revenue from the sale of its GROH line and mushroom-based nutraceutical dietary supplement products and functional ingredients.